TICKERNERD
Menu
FENCFENCHealthcare · Biotechnology

FENC Stock Forecast: Fennec Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Nov 2026
$11
+0.66% on the day

The 5 Wall Street analysts covering Fennec Pharmaceuticals, Inc. hold a median 12-month price target of $18 — +69.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 11 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$373.1M
Ticker Nerd rank
83/ 100
Median analyst target
$18
Analysts covering
5
Revenue$17.9M+85.2% y/y
Operating income$1.7M
Net income$2.0M
Free cash flow$50K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.9%
1M
−0.6%
YTD
+38.3%
1Y
+34.5%
From 52W high
−16.7%
From 52W low
+84.6%
$6
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FENC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fennec Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Nov 2026
83/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
89
Growth
88
Momentum
76
Volatility
75
Value
73
Issuance
72
Size
57
Revisions
49
Accruals
18

Quality (89): The business earns solid, repeatable profits on what it owns.

Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FENC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FENC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14$16$18Jan 26Apr 26Jul 26Oct 26FENCHigh $18Median $18Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $16Median $18High $18

The green dot is the last close — the median target sits +69.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026HC Wainwright & Co.ReiteratesBuy$16
12 Aug 2026B. Riley SecuritiesReiteratesBuy—
12 Aug 2026WedbushMaintainsOutperform—
22 May 2026HC Wainwright & Co.MaintainsBuy—
16 Apr 2026WedbushReiteratesOutperform—
9 Jan 2026Piper SandlerInitiatesOverweight—
21 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025Craig-HallumMaintainsBuy—
20 May 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2025Craig-HallumMaintainsBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.MaintainsBuy—
14 Aug 2024Craig-HallumMaintainsBuy—
15 May 2024Craig-HallumMaintainsBuy—
15 May 2024HC Wainwright & Co.MaintainsBuy—
4 Apr 2024HC Wainwright & Co.MaintainsBuy—
18 Mar 2024Craig-HallumMaintainsBuy—
4 Aug 2023HC Wainwright & Co.MaintainsBuy—
21 June 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

FENC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FENC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Nov 2026, Fennec Pharmaceuticals, Inc. returned +34.5% against +12.4% for the S&P 500, dividends included.

FENC vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26FENCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FENC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+8.8%
Analysts raising
4
Analysts cutting
1
Fundamentals

Fennec Pharmaceuticals, Inc. (FENC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
60.4×

Cheaper than 11% of US stocks

Price / sales
6.3×

Cheaper than 19% of US stocks

Price / book
8.8×

Cheaper than 10% of US stocks

EV / EBITDA
−324.9×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
85.2%

Higher than 91% of US stocks

Earnings growth (YoY)
85.2%

Higher than 82% of US stocks

Gross margin
96.0%

Higher than 98% of US stocks

Operating margin
−1.9%

Higher than 64% of US stocks

Net margin
−5.5%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−18.6%

Higher than 32% of US stocks

Return on assets
−1.2%

Higher than 39% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Fennec Pharmaceuticals, Inc. (FENC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fennec Pharmaceuticals, Inc. has a market value of $373.1M and an enterprise value of $331.9M.

  • Revenue in the twelve months to 30 June 2026: $59.2M. The latest quarter grew 85.2% year on year.

  • Net income over the same four quarters: −$3.3M, a −5.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.13.

  • Free cash flow in the twelve months to 30 June 2026: −$2.0M.

  • Shares outstanding: 35.0M.

  • Trailing P/E: 60.4×; forward P/E: 11.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Fennec Pharmaceuticals, Inc. employs 35 people — $1.7M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Nov 2026

Data provided by Twelve Data

Peers

FENC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FENCFennec Pharmaceuticals, Inc.$373.1M83
PEPGPepGen Inc.$364.3M55
EDITEditas Medicine, Inc.$365.2M71
EIKNEikon Therapeutics, Inc.$360.8M2
ALTAltimmune, Inc.$375.1M27
CCCCC4 Therapeutics, Inc.$379.5M64
FTHFaeth Therapeutics, Inc.$344.1M35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fennec Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FENC news & analysis

Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 12 Nov 2026positive

Fennec Pharmaceuticals reported third-quarter 2026 net product sales of $19.4 million, up 56% year over year, and non-GAAP adjusted EBITDA of $5.8 million. The company said $6.7 million in positive operating cash flow brought its cash position to $48.7 million, with a record number of patients and planned infusions carried into the fourth quarter.

Why it matters — The results provide FENC watchers an update on quarterly sales growth, profitability, cash generation, and patient activity entering the next quarter.

Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026

GlobeNewsWire · 6 Nov 2026neutral

Fennec Pharmaceuticals said it will release third-quarter 2026 financial results before U.S. markets open on November 12, 2026. Management will hold a conference call and webcast that day to discuss the results and business.

Why it matters — FENC watchers can note the scheduled date and time for the company's quarterly results and management discussion.

FAQ

Frequently asked questions about FENC stock

What is the FENC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Fennec Pharmaceuticals, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FENC stock a buy right now?

Of the 5 analysts covering Fennec Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fennec Pharmaceuticals, Inc. 83 out of 100 across roughly 4,600 US stocks as at 11 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FENC?

As at 11 Nov 2026, Fennec Pharmaceuticals, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (89 of 100).

Will FENC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +69.0% from the last close, and Ticker Nerd's factor model ranks Fennec Pharmaceuticals, Inc. 83 out of 100 as at 11 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FENC stock forecast for 2030?

No analyst covering Fennec Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FENC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $18 over the next 12 months.

How has FENC stock performed over the past year?

Fennec Pharmaceuticals, Inc. returned +34.5% over the 12 months to 11 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fennec Pharmaceuticals, Inc. do?

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments that address ototoxicity, a form of hearing damage associated with certain cancer therapies.

What is the latest news on FENC?

The most recent item we track (GlobeNewsWire, 12 Nov 2026): "Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update". Fennec Pharmaceuticals reported third-quarter 2026 net product sales of $19.4 million, up 56% year over year, and non-GAAP adjusted EBITDA of $5.8 million. The company said $6.7 million in positive operating cash flow brought its cash position to $48.7 million, with a record number of patients and planned infusions carried into the fourth quarter.

Company

About Fennec Pharmaceuticals, Inc.

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments that address ototoxicity, a form of hearing damage associated with certain cancer therapies. Its lead product, PEDMARK, is designed to reduce the risk of platinum-induced hearing loss in pediatric patients receiving cisplatin-based chemotherapy. The company operates in the biotechnology and oncology supportive-care markets, serving hospitals, pediatric oncology specialists, and healthcare providers involved in cancer treatment. Based in Research Triangle Park, North Carolina, Fennec Pharmaceuticals is positioned as a commercial-stage company centered on a targeted therapy that supports quality of care for children undergoing chemotherapy.

CEO Mr. Jeffrey S. Hackman · 35 employees · United States · https://www.fennecpharma.com